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Introduction
The aim of vestibular schwannoma (VS) surgery is complete
tumor resection and preservation of nerve function.Wehave
demonstrated that small tumors as well as medium to large
tumors can be offered initial conservative management.1
However, some do grow and need further treatment, such
as radiation therapy or microsurgery. While stereotactic
radiosurgery (SRS) is very successful in the medium term,2
microsurgery may be the only or best option for some
patients. The aim of VS surgery is preservation of nerve
function and complete removal of the tumor, and this iswhat
patients want.3 The size of the tumor among other factors
influences the rates of hearing nerve preservation4 and facial
nerve function.5 While removing tumor, the surgeon must
balance the risk of complete tumor removal against preser-
vation of cranial nerve function. Facial nerve palsy is devas-
tating for the patient.6 This decision is aided by information
on the growth rate of residual VS.7,8 If fragments of tumor are
left behind, Caye-Thomasen and co-workers have demon-
strated that the majority of residual VS spontaneously re-
gress or do not grow, possibly due to disruption of the blood
supply during surgery.9 There is a perception that the risk of
regrowth is related to the size of the residual, its location, and






Abstract Objectives To analyze growth of residual vestibular schwannoma (VS) following
incomplete tumor resection and determine the influence of residual location and size.
Design Retrospective case note and scan review.
Setting Tertiary skull base unit.
Participants Patients with residual tumor following primary surgery for medium and
large unilateral growing vestibular schwanomas between 2006 and 2009.
Main Outcome Measures Location of residual VS and post-operative growth, com-
paring those with more (>5%) or less than 5% of tumor residual (<5%).
Results Fifty-two patients had visible residual tumor left behind at surgery. Twenty
had < 5% and 32 had > 5% residual. The residual growth rates were 38% overall, 20%
in < 5%, and 50% in > 5% residuals. There was no significant difference in growth rates
at different residual locations. Median follow-up was 6.4 years.
Conclusions There is a greater risk of regrowth of residuals > 5%. All positions of
residual tumor can regrow, and the preoperative tumor size plays a role in this. Further
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There has been a trend toward leaving more tumor behind
on the facial nerve and on other vital intracranial structures to
improve functional outcomes during VS surgery. However, the
location of these tumor fragments andhow this predisposes to
regrowth has not been adequately investigated. Bloch et al10
investigated their residual VS growth rate in 79 cases and
found that all recurrences occurred in the mid-cerebellopon-
tine angle (CPA) with none foundwithin the internal auditory
canal (IAC). Kameyamaet al12 similarly suggested in his article
examining 11 patientswith residual tumor that regrowthwas
less likely in the IAC.
In the Liverpool skull base unit, we followed the trend to
leavemore tumor behind to preserve function, and this article
reviews the time when this was practiced to a greater degree
than it currently is. The audit of these results has led to a swing
backof the pendulum, andmore tumor is nowbeing removed.
We aimed to examine our residual VS preoperatively from
growing tumors and ascertain a pattern of growth from a time
when we left behind larger VS residual than we would do
currently. Theprimaryquestionswewanted toanswerwereas
follows: (a) Was there any correlation between the risk of
regrowth and the amount of tumor left behind at surgery, and
(b) was there a difference in growth risk depending on where
residual tumor was left behind?
Methods
The authors assert that all procedures contributing to this
work comply with the ethical standards of the hospital’s
institutional audit and clinical governance department.
A retrospective reviewof case notes andmagnetic resonance
(MR) scans was undertaken of patients treated between 2006
and 2009withmedium- to large-sized sporadic VSwhohad not
had prior active treatment. These we defined as tumors greater
thanorequal to20 mminmaximumintracranialdiameter.Only
growing tumors that underwent surgery were included in the
study, although threepatientswhohad large tumorsunderwent
planned debulking without a period of observation. Patients
who underwent surgery were identified from the operating
theater database. The size of the tumor was assessed from the
radiology report andmeasured the largest diameter in the CPA.
The extent of tumor excision varied between patients. Two
groupswere identified from the postoperativeMR scans: over
95% of tumor excision and less than 95% of tumor. For the
purpose of this article, less than 95% tumor excision was
defined as subtotal, andgreater than 95% excisionwas defined
as near total excision.13–16 However, as there is no interna-
tionally accepted definition of these terms, we report the size
of tumor left behind, i.e., more or less than 5%. Some authors
refer to microscopic fragments of tumor being left behind as
being near total.
The MR scans were studied to document the size of the VS
remnant and also the locationwithin the IAC and/or the CPA by
the authors Guleed H. Adan and Alaina Beacall. In addition,
authorAnandV. Kasbekar double checked allmeasurements to
ensureconsistency.Measurementmethodsconformedtothose
proposedbyKanzaki et al at the2003-consensusmeetingonVS
reporting.17Residual tumorsizewasrecordedat four sites (CPA,
porus, meatus, and fundus), each with the largest two perpen-
dicularmeasurements. Thiswasundertakenwith themeasure-
ment tool of the radiology viewing software (Carestream Vue
PACS,CarestreamHealth Inc.,UnitedStates).►Fig. 1 displaysan
MR image of VS preoperatively and after surgery, demonstrat-
ing tumor left along the facial nerve.
Growth of tumor was defined as at least a 1-mm growth in
tumor dimension in any plane and was confirmed by three
independent investigators. A growth of 1 mm could be consid-
ered insignificant; usually for growth to be confirmed, a 2-mm
change in dimension is required due to the variation in scan
slices and interpretation by single observers. In this study, we
used multiple observations to reduce this variation to allow a
smallerdimension to representgrowth. Inaddition, as thiswasa
retrospective review, we had the benefit of the radiologist’s
report documenting growth. The decision on whether a tumor
was growing or not was discussed and agreed at our multi-
disciplinary team meeting, which included a neuroradiologist,
radiation oncologist, ear, nose, and throat (ENT) surgeon, and
neurosurgeon. The time taken from surgery to the last MR
measurement of the residual tumor was used to calculate the
rate of any growth in millimeters per year (mm/year).
Statistical analysis was performed using SPSS version 22
(IBM UK Limited, United Kingdom). Chi-squared test, Fisher’s
exact test, and correlation coefficient tests were performed
where stated in the results. Logistical regression analysis was
undertaken when comparing different variables that might
affect residual tumor growth. A level of p < 0.05 was set for
significance.
Results
Between2006 and2009, 67mediumand large growing spora-
dic VS had surgical treatment. Of these, 12 cases were not
primarily operated on and were excluded due to previous
radiotherapy.Of theremaining55cases, 3hadnovisible tumor
left at surgery or on postoperative MR scan. The remaining 52
(95%) of resected tumors had some residual tumor left behind,
which was visible on postoperative scanning. All 52 cases that
had residual tumor left behind at surgery were analyzed. The
average preoperative sizewas 27 mm(range: 20–42mm). The
surgical approach was by the retrosigmoid route in 45 cases
and by the translabyrinthine route in 7. Of the 52 residual VS,
20 (38%) grew. ►Table 1 shows the breakdown of growth of
residuals following less or greater than 95% excision. Twenty
percent grew following more than 95% resection, compared
with 50% following less than 95% resection. This was statisti-
cally significant (chi-squared test, p < 0.01). All patients un-
derwent postoperativeMR scanning at 3months to determine
the extent of tumor excision. If tumor was detected, a further
scan at 1 year was undertaken. Follow-up of patients ranged
from 4.5 to 8.1 years (mean: 6.4 years). Time to growth varied
from 1 to 5.5 years (mean: 2.8 years).
Three patients had planned debulking of their large tumors
andwereclassifiedas less than95%resections.All threeof these
tumors grew and required further treatment. Overall, 17 of the
20 growing residual tumors required retreatment. Treatment
was offered after the residual tumor showed evidence of
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growth on serial MR scanning. New symptomatology was also
taken into consideration. Thirteenof these growing tumorshad
radiotherapy, mainly SRS. Three had further surgery followed
by radiotherapy, and one patient underwent revision surgery.
►Table 2 demonstrates the four locations where VS rem-
nants were left behind. Most (47/52) cases hadmultiple sites of
Fig. 1 (A) Preoperative image of VS to be excised. (B) First postoperative MR image demonstrating residual VS along the facial nerve and on the
brainstem. MR, magnetic resonance; VS, vestibular schwannoma.
Table 1 Tableshowingtheproportionofgrowingandnongrowing












Abbreviation: VS, vestibular schwannoma.
Note: Chi-squared test was significant at p < 0.01 indicating a greater
risk of residuum growth with subtotal excision.
Table 2 Tabledemonstratingthefour locationswhereVS remnant











CPA 27 21 (44%) 48 2 (1–7)
Porus 36 11 (23%) 47 2 (1–3)
Meatus 28 14 (33%) 42 1 (1–3)
Fundus 12 2 (14%) 14 1
Abbreviations: CPA, cerebellopontine angle; VS, vestibular
schwannoma.
Note: One tumor could have residual VS at all four locations. Themedian
rate of growth at each site calculated as millimeters per year (mm/y) is
also provided. Fisher’s exact test showed that there was no difference in
the risk of growth comparing all four sites (p ¼ 0.09).
Forty-seven cases had multiple sites of residual tumor and therefore the
total number are greater than 52.
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residual tumor; therefore, one tumor may have residual tumor
atall foursites.►Table 2 alsoprovides themedianrateofgrowth
at each site calculated in mm/year. Fisher’s exact test showed
that therewas no difference comparing all four sites for residual
regrowth (p ¼ 0.09). Therewas also no significant difference in
the growth behavior of tumor within the IAC as awhole (porus,
meatus, and fundus) and the CPA (p ¼ 0.158, chi-squared test).
Residual tumor at the fundus did show a lower percentage of
regrowth rate although the numbers were too small to perform
statistical analysis on.When looking at the preoperative VS size
and the amount of tumor left behind at surgery, there was a
positive correlation found (Spearman’s correlation, rho ¼ 0.56,
p < 001). In other words, the larger is the size of the VS, the
greater is the risk of leaving tumor behind. Logistic regression
analysis demonstrated that age was not a significant factor in
risk of residual tumor regrowth, but preoperative VS size was.
For every 1-mm increase in preoperative VS size, there was an
11% increase inoddsof the residualVSgrowing, if tumorwas left
behindat surgery. In addition,weanalyzedwhether theamount
of tumor left at surgery was associated with regrowth rate and
found that there was no correlation between the postoperative
residual tumor size and regrowth rate (Pearson’s correlation
coefficient, r ¼ –0.12, p ¼ 0.741).
Discussion
Studies around the behavior of residual VS are reliant on the
accuracy of measuring tumor remnant after surgery. Intrao-
perative estimation of the amount of tumor left behind is
notoriously difficult, and an MR scan is recommended post-
operatively to assess for residual tumor.16 Linear enhancement
of thebrain,dura, andwithin theoperativefieldafter surgery is
commonly seen.18 Neuroradiologists are now instructed to
look for a nodular enhancement pattern, which more accu-
rately detects residual tumor.19 It is known that definitions of
the extent of surgical resection often differ in publications.20
Some authors have tried to quantify the amount of resection
intraoperatively16 or with a fixed measurable amount of
tumor seen postoperatively on the MR scan.10 We grouped
the tumor excisions into two groups; over 95% of tumor
excision and under 95% of tumor excision. This is commonly
referred to asnear totalor subtotal resection, respectively.13–16
In our series of medium to large growing VS being treated,
95% of patients had some fragments or residual tumor left
behind. This was due to the understanding at the time that
complete tumor removal predisposed to poorer facial nerve
function.21 The rates of residual tumor regrowth were also
thought to be low.7,12,22–24
Furthermore, there are reports of near total as well as
subtotal resections, which did not show any residual tumor
on the postoperative MR scan.9 It is thought that devascular-
ization of the tumor following surgery is the reason for the
disappearance of residual tumor. Recent published articles
havequotedregrowthratesofapproximately30%withsubtotal
VS resections,10,12,16,20 although El-Kashlan et al had a 71%
regrowth rate in subtotal resections.25Sughrueet al24 reported
one of the very few contrasting publications that found no
difference in regrowth rates between near total and subtotal
resections. They also had a very low, 8.8%, regrowth rate. Our
regrowth rate was 38%, mainly occurring in less than 95%
resections. Four of the 16 more than 95% resections grew
within thefollow-upperiod, and the literaturequotes regrowth
rates of 3 to 19% in this group of patients.10,12,20 The difference
in our regrowth rates between less than and greater than 95%
resectionswas statistically significant (p < 0.01) and is similar
to those results previously documented in the literature.10,20,26
The growth of residual tumor has been shown previously to
be independent of age and sex,11 although there is some
evidence that the elderly people have slower growing tu-
mors.11,27 We performed logistic regression analysis on our
series and also confirmed that agewas not a significant factor in
the growth of residual tumor. We found preoperative VS size to
be significant predictor for growthof a residual tumor. For every
1-mm increase in preoperative VS size, there was an 11%
increase in odds of the residual VS growing, if tumor was left
behind at surgery. Thismay be due to larger tumors beingmore
aggressive in nature to reach such a size by the time of
presentation.There isalsoagreaterprobabilityof residual tumor
being left behind at surgery for larger tumors as this improves
post-operative facial nerve outcomes.26 We found preoperative
VS size to be significantly positively correlatedwith the amount
of tumor left behind (Spearman’s correlation, rho ¼ 0.56,
p < 001). In a large series of 1,143 patients, Hahn et al also
foundthis tobetrue.9Ourfindingsaddtothecompellingbodyof
evidence that the size of a tumor being operated on has direct
consequences on whether residual tumor will regrow.
Although larger VS remnants aremore likely to regrow,20,26
the size of the residual tumor did not seem to be related to the
rate at which they grow (Pearson’s correlation coefficient,
r ¼ –0.12, p ¼ 0.741).
In our series, three of the less than 95% resections were
planned as partial removals due to the large tumor size and
health of the patients, and all of these residual tumors grew.
This difference in regrowth rates between publications can
partly be explained by the varied definitions of subtotal and
near total resections, what defines tumor growth and also the
length of follow-up. Some of the higher recurrence rates may
alsobeexplainedbythefact that thesetumorsweregrowingat
the time of surgery, as in our series. There is, therefore, a need
for standardized reporting within the literature.
Time to regrowth varied between 1 and 5.5 years with a
mean time of 2.8 years. This is broadly in line with current
literature that identified growth at approximately 3 years
following the initial surgery.10,11,19Ourdata show that growth
can occur 5.5 years after surgery, and it is interesting to note
that several studies published do not have a long enough
follow-up period to document late growth.10,16 Ideally, we
feel that studies reporting on tumor regrowth should show a
follow-up of at least a median of 6 years. In clinical practice,
residual tumors should be followed up for life.
Of the 20 growing residual tumors, 17 (85%) required treat-
ment, mainly in the form of radiosurgery. The published litera-
ture quotes figures ranging from 0 to 100% of growing residual
tumors that require treatment, which tends to be in the form of
radiosurgery.20 Further discussion around the treatment of
growing residual tumors is beyond the scope of this article.
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The distribution of residual tumor left behind at surgery
illustrates that the majority are at the CPA, along the brain-
stem where the tumor is likely to be adherent to critical
structures. Ninety-two percent of residual VS had a remnant
left behind at the CPA. The porus was equally likely to have
remnant left behind at 90%. Some VSwas often left along the
length of the facial nerve, and 90% of cases had tumor atmore
than one site.
Although there have been reports that tumor remnants in
the IAC are less likely to grow, the data is limited.5 ►Table 2
displays in our series whether residual VS was growing or
not at a particular site and also the rate of residual VS
growth in mm/year. This did not show any difference in
growth rate in relation to the residual tumor site. The fundus
showed the lowest growth rate at 14%, but the number of
tumors studied were too small to base conclusions on. The
rate of expansion, however, in growing residual tumor
suggests that CPA fragments are more likely to grow at a
faster rate compared with the meatus and fundus (2 mm/
year versus 1 mm/year). This difference in growth rate is not
significant given the number of cases we have included in
our study. A reason for the reduced growth rate in the IAC
could be the surrounding bony canal that limits rapid
growth. Further limitations of the study include its retro-
spective nature and the lack of facial nerve outcomes,
which may have had an influence on the amount of tumor
excised.
The tendency to leave residual VS predominantly reflects
the change in emphasis in VS surgery from complete tumor
resection to facial nerve preservation. However, it also
coincided with the development of SRS, which provides a
treatment option for residual tumor. There is currently
interest in planned subtotal resections using image guidance
plus or minus intraoperative imaging, followed by adjuvant
SRS.28 We have demonstrated high (50%) growth rates in
residual tumors following subtotal resection, which are
significantly reduced by a more aggressive resection. We
would advocate that the aim of surgery should remain as
complete a resection as possible with preservation of the
facial nerve. Patients with residual VS following surgery
should be monitored closely for an indefinite period. The
size of the tumor should be borne in mind when deciding on
the surgical strategy and potential postoperative treatment
in patients with growing tumors. Our data show that tumor
growth occurs at all sites and that the preoperative size of the
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